Diffussion Pharma Inc. (NASDAQ:DFFN) jumped 4.5% on no company-specific news or release. Recently, the company released a topline result for the phase 1 study of its flagship product, trans sodium crocetinate (TSC).
The company used transcutaneous oxygen monitoring hg in the trial to assess direct TSC pharmacodynamics effects on peripheral oxygenation of tissue in healthy individuals. The topline findings were based on primary endpoint data analysis which showed a promising dose-response trend relative to placebo. However, because of a small number of participants in each group and that intrinsic tcpO2 measure variability, the extent of the impact was statistically not significant.
Interestingly the primary endpoint results showed enhanced peripheral oxygenation relative to placebo without signs of hyperoxygenation. The trial was among the three oxygenation studies the company will conduct this year, including DLCO and Altitude trials. The company expects to complete the Altitude and DLCO trials in the second half of 2021, with results expected in two months of completion. With the encouraging findings, DFFN is worth watching.
On Tuesday, DFFN stock leaped 4.36% at $0.5691 with more than 2.22 million shares, compared to its average volume of 1.61 million shares. The stock has moved within a range of $0.5406 – 0.5979 after opening the trade at $0.55.